About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Sanofi Ceases Development of Glenmark’s Multiple Sclerosis Drug Due to Efficacy Concerns

by Reshma Anand on October 31, 2015 at 2:52 PM
Font : A-A+

Sanofi Ceases Development of Glenmark’s Multiple Sclerosis Drug Due to Efficacy Concerns

After facing safety issues during the phase- II trial of a multiple sclerosis (MS) drug, the French drug maker Sanofi has stopped its development. Vatelizumab is the drug that was first developed by the Indian Pharmaceutical company, Glenmark.

Sanofi obtained the license for that drug from Glenmark in a $600 million deal in 2011. This was the first licensing deal for a original product by Glenmark.

Advertisement

The drug was developed as a potential treatment for relapsing-remitting multiple sclerosis. But the drug failed to reach the desired level of efficacy in a mid-stage trial.

"Sanofi's decision was not due to any safety concerns, we will continue to pursue the relicensing of GBR 500 after it's returned from Sanofi," said Glenmark.

The drug candidate is believed to block VLA-2 on activated immune cells, leading to interference with collagen-binding in areas of inflammation and thus may reduce the inflammatory cascade in MS, reasoned Glenmark and Genzyme, a Sanofi company.

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge About Chromosomes?
Eating During Sunlight Hours Minimizes Mood Vulnerabilities
Know More About the Digestive System
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Chemotherapy Chemotherapy Drugs Signature Drug Toxicity Infectious Mononucleosis Multiple Sclerosis Treatment and Modify Optic Neuritis Autoimmune Disorders Health Risks of Eating Pork 

Most Popular on Medindia

Daily Calorie Requirements Post-Nasal Drip Selfie Addiction Calculator Blood - Sugar Chart Hearing Loss Calculator Iron Intake Calculator Indian Medical Journals Sanatogen Calculate Ideal Weight for Infants Drug - Food Interactions
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Sanofi Ceases Development of Glenmark’s Multiple Sclerosis Drug Due to Efficacy Concerns Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests